Home › NDC Lookup › RxCUI directory › RxCUI 2383305

10 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 60 MG/ML / trastuzumab-zzxf 60 MG/M... — RxCUI 2383305

RxNorm drug concept · Semantic clinical drug
RxCUI 2383305 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2383305
Official name10 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 60 MG/ML / trastuzumab-zzxf 60 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aspertuzumab-trastuzumab-hyaluronidase-zzxf 600 MG / 600 MG / 20,000 UNT per 10 ML Injection; pertuzumab-trastuzumab-hyaluronidase-zzxf 600 MG / 600 MG / 20,000 UNT in 10 ML Injection
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)6,412 prescriptions · 39 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pertuzumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Perjeta is a targeted therapy specifically designed for cancers that overexpress a protein called HER2. It works by attaching to the HER2 protein and blocking it from sending the g...
  • What exactly is Perjeta and why do I need it alongside other medicines?
  • Perjeta is given as an IV infusion by your care team in a clinic or infusion center — it goes directly into your vein through a drip. Each infusion takes between 30 and 60 minutes,...
  • How will I receive Perjeta, and how long does it take?
📖 Read our full Pertuzumab Injection guide →

🕸️ Concept Web — How 10 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzuma... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 10 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 60 MG/ML / trastuzumab-zzxf 60 MG/ML Injection RxCUI 2383305

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 7

    The active substance itself — no strength, form, or brand attached yet.

    • Hyaluronidase 5464
    • Pertuzumab 1298944
    • Trastuzumab 224905
    • Hyaluronidase / pertuzumab / trastuzumab 2382603
    • Hyaluronidase-zzxf 2382595
    • Pertuzumab-zzxf 2382597
    • Trastuzumab-zzxf 2382599
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Phesgo 2382605
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyaluronidase / pertuzumab / trastuzumab Injection 2382602
    • Hyaluronidase-zzxf / pertuzumab-zzxf / trastuzumab-zzxf Injection 2645961
    • Hyaluronidase / pertuzumab / trastuzumab Injectable Product 2382601
    • Hyaluronidase-zzxf / pertuzumab-zzxf / trastuzumab-zzxf Injectable Product 2661089
    • Hyaluronidase / pertuzumab / trastuzumab Injection [Phesgo] 2382607
    • Hyaluronidase-zzxf / pertuzumab-zzxf / trastuzumab-zzxf Injection [Phesgo] 2656804
    • Phesgo Injectable Product 2382608
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 21 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Hyaluronidase-zzxf 2000 UNT/ML SCDC · 2382596
  • Pertuzumab-zzxf 60 MG/ML SCDC · 2382613
  • Trastuzumab-zzxf 60 MG/ML SCDC · 2382614
  • Hyaluronidase / pertuzumab / trastuzumab Injection SCDF · 2382602
  • Hyaluronidase-zzxf / pertuzumab-zzxf / trastuzumab-zzxf Injection SCDFP · 2645961
  • Hyaluronidase / pertuzumab / trastuzumab Injectable Product SCDG · 2382601
  • Hyaluronidase-zzxf / pertuzumab-zzxf / trastuzumab-zzxf Injectable Product SCDGP · 2661089

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2383305 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50242-0245-01 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-01) / 15 mL in 1... Phesgo Genentech, Inc. 2020-06-29
50242-0245-86 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-86) / 15 mL in 1... Phesgo Genentech, Inc. 2021-05-03
50242-0260-01 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-01) / 10 mL in 1... Phesgo Genentech, Inc. 2020-06-29
50242-0260-86 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-86) / 10 mL in 1... Phesgo Genentech, Inc. 2021-05-03
Observed labelers: Genentech, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9316 Pertuzu, trastuzu, 10 mg 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.